Skip to content

Effect of preventive multimodal analgesia on pain control and rapid postoperative recovery in adult patients undergoing thoracoscopic pulmonary resection: a prospective, multicenter, randomized controlled study

Effect of preventive precision multimodal analgesia on pain control and rapid postoperative recovery in adult patients undergoing thoracoscopic pulmonary resection: a prospective, multicenter, randomized controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300072176
Enrollment
Unknown
Registered
2023-06-05
Start date
2023-08-30
Completion date
Unknown
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative pain following video-assisted thoracoscopic surgery

Interventions

PPMA group:preventive precision multimodal analgesia
CMA group:Conventional multimodal analgesia

Sponsors

Xuanwu Hospital of Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Adult patients aged 18-65 years; 2. Adult patients undergoing elective thoracoscopic lobectomy or segmental lung resection under general anesthesia; 3. ASA classification I to III; 4. BMI of 18.5 to 29.9 kg/m2; 5. Informed patient consent obtained.

Exclusion criteria

Exclusion criteria: 1. History of surgery under general anesthesia within one month prior to surgery; 2. Preoperative coexisting severe cardiopulmonary and cerebral systemic diseases, such as severe hypertension (crisis), severe diabetes (ketosis, acidosis), coronary artery disease, COPD, asthma, respiratory failure, pulmonary hypertension, severe arrhythmias (atrial fibrillation, atrioventricular block of degree II or higher, sick sinus syndrome, etc.), severe heart valve disease, heart failure, renal failure Patients with stroke, myocardial infarction within 6 months, Alzheimer's disease, Parkinson's disease, psychiatric disease, OSAS, myasthenia gravis, etc.; 3. History of chronic pain; 4. Hepatic and renal insufficiency and leukopenia; 5. History of allergy to the drugs used in this study; 6. History of inflammatory bowel disease or peptic ulcer; 7. Coagulation abnormalities; 8. Patients with METs < 4; 9. Patients who refused or were unable to cooperate in this study; 10. Participating in other studies within 30 days.

Design outcomes

Primary

MeasureTime frame
duration of pain;

Secondary

MeasureTime frame
Total postoperative opioid dosage;Number of NSAIDS drug remediation and total remediation dosage;PCIA first Time to compression and total number of PCA compressions;Patients' postoperative VAS scores of resting pain and motor pain and pain control satisfaction scores at 2h, 6h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, before discharge, 5min before drain removal and 5min after drain removal at rest and during coughing at each time point;Perioperative Hemodynamic Parameters and IoC Awareness Injury Index;Results of blood gas analysis and ventilation monitoring at established time points;Intraoperative general anesthetic dosage;QoR-15 scores, PONV scores,HAD/HAMD and blood cortisol, CRP, LPS, and PGE amounts at established postoperative time points;Patients resume bowel evacuation time, resume drinking time, resume eating time;Postoperative drainage tube drainage, drainage tube removal time and length of stay (LOS);

Countries

China

Contacts

Public ContactTianlong Wang

Xuanwu Hospital of Capital Medical University

w_tl5595@hotmail.com+86 139 1052 5304

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 23, 2026